Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium dificile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its microbiom... More

Recent NewsMore
08/11/16
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Progress Update
- Comprehensive review of initial SER-109 Phase 2 study data underway - - Strong cash position to support operations well into 2018, and through the anticipated Phase 1b study read-outs for SER-287 and SER-262 – - Conference call at 8:30 AM ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 11, 2016-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today reported second quarter... 
08/05/16
Seres Therapeutics to Host Second Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on August 11, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2016 at 8:30 a.m. ET to discuss second quarter 2016 results. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160805005067/en/ To access t... 
07/29/16
Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection
- Primary efficacy endpoint was not achieved - - Conference call at 8:30 AM ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 29, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced interim 8-week results from the ongoing SER-109 Phase 2 ECOSPORTM clinical study for the prevention of multiply recurrent Clostridium difficile infection (CDI). The study’s primary endpoint of r... 
EventsMore
There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$13.06
 - 0.34 (2.54%)
09/26/16 1:09 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.